{"issuance_frequency":"","notes_translated":{"fr":"Fournir aux promoteurs qui soumettent une présentation de drogue nouvelle les renseignements nécessaires pour se conformer à l'alinéa C.08.002(2)h), au sous-alinéa C.08.002.1(2)c)(ii) et au paragraphe C.08.003(3) du Règlement sur les aliments et drogues (le Règlement) en ce qui concerne les études de biodisponibilité comparatives utilisées pour établir l'innocuité et l'efficacité d'un médicament.","en":"To provide sponsors of new drug submissions with the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations (Regulations) with respect to comparative bioavailability studies used in support of the safety and efficacy of a drug."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"0c997f9f-5825-4702-b01c-dc6b79279197","metadata_created":"2021-06-01T17:31:45.862583","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-01T17:31:45.862606","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-01","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["document d'orientation","conduite et analyse","études comparatives de biodisponibilité","équivalent pharmaceutique","exigences en matière de données et critères"],"en":["guidance document","conduct and analysis","comparative bioavailability studies","pharmaceutically equivalent","data requirements and criteria"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice : Conduite et analyse des études de biodisponibilité comparatives","en":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"0c997f9f-5825-4702-b01c-dc6b79279197","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"a9afc90c-f8ed-4d3d-a837-3eebb30898f7","related_relationship":"","name_translated":{"fr":"Ligne directrice : Conduite et analyse des études de biodisponibilité comparatives","en":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies","language":["en"],"created":"2021-06-01T17:31:45.923347","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/conduct-analysis-comparative.html","last_modified":null,"position":0,"revision_id":"62919050-85e1-456b-bf49-94382ee5b0f0","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"0c997f9f-5825-4702-b01c-dc6b79279197","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"4897b660-eb15-4c8a-b521-6a18241d959b","related_relationship":"","name_translated":{"fr":"Ligne directrice : Conduite et analyse des études de biodisponibilité comparatives","en":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies","language":["fr"],"created":"2021-06-01T17:31:45.923352","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/biodisponibilite-bioequivalence/conduite-analyse-etudes.html","last_modified":null,"position":1,"revision_id":"62919050-85e1-456b-bf49-94382ee5b0f0","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2018-09-01 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"0c997f9f-5825-4702-b01c-dc6b79279197","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"To provide sponsors of new drug submissions with the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations (Regulations) with respect to comparative bioavailability studies used in support of the safety and efficacy of a drug.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document: Conduct and Analysis of Comparative Bioavailability Studies","revision_id":"62919050-85e1-456b-bf49-94382ee5b0f0"}